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INTRODUCTION 
 
The thyroid gland maintains the level of metabolism in the tissues 
that is optimal for their normal function. Thyroid hormones stimulate oxygen 
consumption of most of the cells in the body, and regulates carbohydrate and lipid 
metabolism. Thyroid function is regulated by Thyroid stimulating hormone (TSH). 
Hypothyroidism, a state of deficient thyroid hormones, may be result of many 
etiologies. Hypothyroidism can affect all organ systems, including cardiovascular 
system. 
The cardiovascular manifestations can be like systolic dysfunction, 
diastolic dysfunction, pericardial effusion,  ECG  changes , coronary artery disease 
and congestive cardiac failure. These dysfunctions can also be contributed by 
hypertension, hypercholesterolemia which are part of hypothyroidism. Some 
studies suggest that abdominal aortic atheroscerosis can occur even in mild 
hypothyroidism. 
An understanding of pathophysiology of cardiovascular changes in 
hypothyroidism enables prevention, early diagnosis and prompt intervention to 
control complications. Also the presence of cardiovascular complications may 
necessitate institution of thyroid hormone replacement in patients of asymptomatic 
hypothyroidism. 
This study is undertaken at Stanley Medical College, Chennai to 
evaluate the cardiovascular changes that accompany various grades of  
hypothyroidism. 
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AIM OF THE STUDY 
 
 
 
  To study the cardiovascular changes in patients with overt primary 
hypothyroidism utilizing echocardiography. 
 
      
 
 
 
 
 
 
 
 
 3
 
REVIEW OF LITERATURE 
 
THYROID HORMONES  
The principal hormone secreted  by the thyroid gland are T4 
thyroxine and tri-iodothyronine.T3 is also formed from peripheral deiodination of 
T4.Both are iodine containing aminoacids.T3 is more active than T4,RT3 is 
inactive.99.98% of T4 is plasma bound, and biological half life is longer(6-7 
days).T3 is less protein bound, so lesser half life. Action of T3 on tissues is more 
rapid. One third of circulating T4 is normally converted to T3.87% of circulating 
T3 is formed by deiodination, only 13% of T3 is formed by thyroid gland. Some 
of the T4 and T3 is further converted into deiodotyrosines.T3 and T4 are also 
converted into glucuronide conjugates that enter the bile and pass into the 
intestine. These conjugates will be excreted in stools.T3 acts more rapidly and is 
3-5 times more potent than T4. 
MECHANISM OF ACTION 
Thyroid hormones enter cells, and T3 binds to thyroid receptors 
(TR) in the nuclei.  T4 can also bind, but not as avidly.  The hormone-receptor 
complex then binds to DNA via zinc fingers and increases or in some cases 
decreases the expression of a variety of different genes that code for enzymes that 
regulate cell function.  Thus, the nuclear receptors for thyroid hormones are 
members of the super family of hormone sensitive nuclear transcription factors. 
 4
 
There are two human TR genes: an alpha receptor gene on 
chromosome 17 and a beta receptor gene on chromosome 3.  By alternative 
splicing, each forms at least two different mRNAs and therefore two different 
receptor proteins.  TR beta2 is found only in the brain, but TR alpha 1, TR alpha2, 
and TR beta1 are widely distributed.  TR alpha 2 differs from the other three in 
that it does not bind T3 and its function is unsettled.  TRs bind to DNA as 
monomers, homodimers, and heterodimers with other nuclear receptors, 
particularly the retinoid X receptor (RXR).  This heterodimer  does not bind 9-cis 
retinoic acid, the usual ligand for RXR, but the TR binding to DNA is greatly 
enhanced.  There are also co activator and co repressor proteins that affect the 
actions of the TRs.  Presumably, this complexity permits thyroid hormones to 
produce their many different effects in the body, but the overall physiologic 
significance of the complexity is still largely unknown. 
In most of its actions, T3 acts more rapidly and is three to five times 
more potent than T4.  This is because it is less tightly bound to plasma proteins but 
binds more avidly to thyroid hormone receptors. RT3 is inert. 
IODINE METABOLISM 
Iodine is a raw material essential for thyroid hormone synthesis. 
Ingested iodine is converted into iodide and absorbed. The minimum daily iodine 
intake  that will maintain normal thyroid function is 150 micro grams in adults, but 
in US the average dietary intake is approximately 500 micro gram per day. The 
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normal plasma iodide level is about 0.3 micro gram per/dl, and iodide is 
distributed in a space of approximately 25 liter(35% of body weight).The principal 
organs that take up the iodine are thyroid, which uses it to make thyroid hormones, 
and the kidneys, which excrete it in the urine. 
About 120 micro gram of iodine per day enter thyroid at normal 
rates of thyroid hormone synthesis and secretion. The thyroid secretes 80 micro 
grams per day as iodine in T3 and T4. 40 micro grams of iodine per day diffuses 
into the ECF. The secreted T3 and T4 are metabolized in the liver and other 
tissues, with the release of 60 micro gram of iodine per day into the ECF. 
Some thyroid hormone derivatives are excreted in the bile, and some 
of the iodine in them is reabsorbed (entero hepatic circulation), but there is a net 
loss of iodine in the stool of approximately 20 micro gram per day. The total 
amount of iodine entering the ECF is thus 500+40+60 or 600 micrograms per day. 
Out of this 600 micrograms of iodine, 20% enters the thyroid gland, whereas 80% 
is excreted in the urine. 
CHEMISTRY AND METABOLISM OF THYROID STIMULATING 
HORMONE(TSH): 
Human TSH is a glycoprotein that contains 211 amino acid residues, 
plus hexoses, hexosamines and sialic acid. It is made up of 2 sub units, designated 
as Alpha and Beta. The alpha sub unit is encoded by a gene on chromosome 6 and 
the beta sub unit by a gene on chromosome 1. The alpha and beta sub units 
become non covalently linked in the thyrotropes. TSH alpha is identical to the 
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alpha sub unit of the leutinising hormones, Follicular stimulating hormones and 
Human Gonodotropic hormone – alpha. The functional specificity of TSH is 
conferred by the beta sub unit. The structure of the TSH varies from species to 
species, but other mammalian TSHs are biologically active in humans.  
The biologic half life of human TSH is about 60 minutes. TSH is 
degraded for the most part in the kidneys and to a lesser extent in the liver. 
Secretion of TSH is pulsatile, and the mean output starts to rise at about 9 pm, 
peaks at mid night, and then declines during the day. The normal secretion rate is 
about 110 micro gram per day. The average plasma level is about 2 micro units per 
ml. 
Since the alpha sub unit in the human chorionic gonodotrophin is the 
same as that in TSH, large amounts of human chorionic gonodotrophin can 
activate thyroid receptor. In some patients with benign or malignant tumors of 
placental origin, plasma HCG levels can rise so high that they produce mild 
hyperthyroidism. 
EFFECTS OF TSH ON THE THYROID 
When the pitutary is removed, thyroid function is depressed and the 
gland atrophies; when TSH is administered, thyroid function is  stimulated. Within 
a few minutes after the injection of TSH, there are increases in iodide binding; 
synthesis of the T3, T4 and iodotyrosines; secretion of thyroglobulin into the 
colloid; and endocytosis of colloid. Iodide trapping is increased in a few hours; 
 7
blood flow increases; and, with chronic TSH treatment, the thyroid cells 
hypertrophy and the weight of thyroid gland increases. 
ACTION OF THYROID HORMONE ON HEART 
Heart is a major target organ for thyroid hormone action , and 
marked changes occur in cardiac function in patients with hypo or hyper 
thyroidism. Changes can be direct effects of thyroid hormone (T3) or indirect 
effects. Direct effects results from direct action on heart either by nuclear or 
extranuclear actions on the cell. Extranuclear effects occur independent of nuclear 
T3 receptor binding and increases in  protein synthesis, influences transport of 
aminoacids, sugars and calcium across cell membrane. 
Nuclear effects are mediated by binding of T3 hormone to specific 
nuclear receptor proteins. T3 causes increased mRNA coding for sarcoplasmic 
reticulum ATPase protein, which leads to increase in the speed of diastolic 
relaxation. 
THYROID HORMONE REGULATION OF CARDIAC GENE 
EXPRESSION 
A. Positively regulated : 
1. Alpha- myosin heavy chain 
2. sarcoplasmic reticulum  
3. Ca++ - ATPase 
4. Na+ , k+ ATPase 
5. Voltage gated potassium channels  
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(KV 1.5 , KV 4.2, KV 4.3) 
6. Atrial and brain natriuretic  peptides 
7. Malic enzymes 
8. Beta adrenergic receptors 
9. Guanine- nucleotide binding protein Gs 
10. Adenine nucleotide transporter 1 
B. Negatively regulated : 
      1.Beta myosin heavy chain 
       2. Phospholamban 
        3.Na+ / Ca++ exchanger 
         4. Thyroid hormone receptor alpha 1 
         5. Adenyl cyclase (AC) 
         6. Guanine nucleotide – binding protein Gi 
HEMODYNAMIC ALTERATIONS IN THYROID DISEASE  
Predictable changes in myocardial contractility and cardiovascular 
hemodynamics occur across the entire spectrum of thyroid disease.1 Multiple 
studies including those in experimental animals as well as invasive and 
noninvasive measurements in patients indicate that T3 regulates cardiac inotropy 
and chronotropy through a variety of direct and indirect mechanisms. 
 Direct effects on vascular smooth muscle cells decrease systemic 
vascular resistance of the arterioles of the peripheral circulation.2 There is a 
decrease in mean arterial pressure and activation of Renin – Angoitensin – 
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Aldosterone system which results in an increase in renal sodium reabsorption. This 
increased sodium reabsorption results in expansion of plasma volume. 
 The increase in plasma volume coupled with an increase in 
erythropoietin leads to an increase in blood volume and rise in cardiac preload. So 
a decrease in the systemic vascular resistance( by as much as 50%) , coupled with 
increase in venous return and preload, increases cardiac output. Cardiac out put 
may be more than double in hyperthyroidism and conversely may decrease by as 
much as 30- 40% in hypothyroidism. Studies using positron emission tomography 
measurements of acetate metabolism have demonstrated that the marked increase 
in cardiac output is accomplished with no change in energy efficiency. 
 T3 appears to reduce systemic vascular resistance by both, direct 
effects on vascular smooth muscle cells and changes in the vascular endothelium 
potentially involving the synthesis and secretion of NO.3 The vasodilatory effect of 
T3 can be observed within hours of administration of T3 in patients undergoing 
coronary artery bypass grafting and in patients with chronic congestive cardiac 
failure. Arterial compliance also falls in hypothyroidism and may explain why 
mean arterial and diastolic pressure are low and peak systolic pressure increases. 
Thus the combination of increased cardiac output and decreased compliance, 
which may be more pronounced in older patients with some degree of arterial 
vascular disease, leads to systolic hypertension in as many as 30% of patients. One 
study showed that the prevalence of hypothyroidism in primary pulmonary 
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hypertension is high.4 In hypothyroidism, 20% of patients have diastolic 
hypertension.5 
EFFECTS OF THYROID HORMONE ON CVS 
1. Decreases total peripheral resistance because of cutaneous 
vasodilatation and this increases sodium and water absorption. 
2. By direct action of thyroid hormone on heart, increases cardiac output. 
3. By indirect action it increases the sensitivity of heart to catecholamines 
which causes increase in heart rate, shortening of circulatory time and 
widening of pulse pressure. 
Above effects are caused by increased production of alpha  2  
myosin heavy chains, sarcoplasmic reticulum Ca++ ATPase, and certain K+ 
channels, and decreased production of beta myosin heavy chains, phospholamban, 
Na+-Ca+ exchanger 
CARDIOVASCULAR CHANGES IN THYROID DISEASE: 
 
Parameter 
 
 
Normal 
 
Hyperthyroid 
 
Hypothyroid 
Systemic vascular 
resistance 
(dyne-cm)sec-5 
 
 
1500 – 1700 
 
 
700 – 1200 
 
 
2100 – 2700 
Heart rate 
(beats per minute) 
 
72 – 84 
 
88 – 130 
 
60 – 80 
Cardiac output 
(liter/ minute) 
 
5.8 
 
>7 
 
<4.5 
Blood volume 
(% of normal) 
 
100 
 
105.5 
 
84.5 
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HYPOTHYROIDISM : Categories  
 1.Goitrous hypothyroidism 
 2. Atrophic hypothyroidism 
 3. Transient hypothyroidism 
 4. Consumptive hypothyroidism 
 5. Central hypothyroidism 
 6. Resistance to thyroid hormone 
Primary hypothyroidism accounts for 99% of cases, with 1% 
account for TSH deficiency, central hypothyroidism. Clinically apparent 
impairment of thyroid function affects about 2% of adult women and 0.1 to0.2% 
of adult men. 
GOITROUS HYPOTHYROIDISM 
Goitrous hypothyroidism can be congenital or acquired. Acquired 
causes are: 
 1. Hashimotos thyroiditis 
 2. Iodine deficiency 
 3. Drugs 
 4. Goitrogens 
 5.Thyroid infiltrations 
Atrophic thyroiditis : can be acquired or congenital. Acquired causes are  
 1. Hashimotos disease 
 2. Iodide/surgery 
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SUBCLINICAL HYPOTHYROIDISM 
Subclinical hypothyroids, defined by a TSH level above the upper 
range of the reference population (usually 5 mIU/ML) is seen in as many as 9 
percent of unselected populations and prevalence clearly increases with advancing 
age.6 In contrast to younger patients, in whom there is a strong female predilection, 
this difference is lost in older populations.  Studies of lipid metabolism, 
atherosclerosis, cardiac contractility, and systemic vascular resistance are altered 
in subclinical hypothyroidism.  Cholesterol levels rise in parallel with increments 
in TSH  elevations starting at 5 mIU/ml. 
 In a large study of women in Rotterdam, it was noted that 
atherosclerosis and myocardial infarction were increased with odds ratios of 1.7 
and 2.3 respectively , in women with sub clinical hypothyroidism.  Interestingly, 
the presence of antithyroid antibodies indicated heightened risk.7 Restoration of 
serum TSH to normal levels after thyroid hormone replacement therapy, improved 
lipid levels, lowered systemic vascular resistance, and improved cardiac 
contractility.8 In patients with subclinical hypothyroidism, isovolumetric 
relaxation times are prolonged while systolic contractile function is unchanged.  
Replacement with L-thyroxin sodium at a mean dose of 68 ug/d (range 50 to 100 
ug/d) restored isovolumetric relaxation times to normal, and compared with those 
in the same patients before therapy, systemic vascular resistance declined and 
systolic function was significantly improved.9 A variety of studies have indicated 
that the changes in systemic vascular resistance may result from alterations in 
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endothelium-dependent vasodilatation.  Taking these findings together, it seems 
appropriate to recommend thyroid hormone replacement for all patients with 
subclinical hypothyroidism from a cardiovascular perspective.  The lack of 
untoward cardiac effects observed when serum TSH levels have been restored to 
normal indicates that the potential benefits far outweigh the risks of treatment.1   
DIAGNOSIS 
Hashimotos disease, radioiodine therapy for Graves disease, and 
iodine deficiency (in parts of the world where that remains a public health 
problem) are the leading causes of hypothyroidism and produce diagnostic 
elevations in serum TSH.  Thus, the finding of elevated TSH is sufficient to 
establish the diagnosis and form the basis for treatment.  In routine practice, 
additional testing with a serum T4 and T3 resin uptake test is confirmatory.  The 
prevalence of hypothyroidism is estimated as 3 to 4 percent for overt disease and 7 
to 10 percent for the milder forms of disease.  Thus, TSH screening can be advised 
for all adults and particularly patients demonstrating hypertension, 
hypercholesterolemia, hypertriglyceridemia, coronary or peripheral vascular 
disease, unexplained pericardial or pleural effusions, and a variety of 
musculoskeletal syndromes.10 
MYXEDEMA COMA 
  It is the ultimate stage of severe long standing hypothyroidism. This 
state invariably affects older patients and occurs most commonly during the winter 
months and associated with a high mortality rate. Usually it is accompanied by 
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subnormal temperature as low as 23 degree celcius have been reported. The 
clinical features include the following: 
          1 . Sinus Bradycardia. 
   2 . Severe hypotension. 
   3 . Delay in deep tendon reflexes or areflexia. 
  4 . seizures usually accompanying coma. 
  5 . External manifestations. 
PATHOGENESIS OF MYXEDEMA COMA – RESPIRATARY   
TRIGGERS 
 
 
Depressed hypoxic 
ventilatory drive 
Obesity, 
sleep apnea 
d
Macroglossia, 
upper airway 
swelling 
Pneumonia 
Respiratory 
muscle 
weakness 
ALVEOLAR 
HYPOVENTILATION CO2 
RETENTION----COMA 
Depressed 
hypercapnic drive
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PATHOGENESIS OF MYXEDEMA COMA –  CARDIOVASCULAR  
CAUSES 
Factors predisposing to myxedema coma are exposure to cold, 
infection, trauma, CNS depressants, anaesthetics, alveolar hypoventilation and 
dilutional hyponatremia. There is considerable difficulties in making the 
diagnosis,because hypothermia due to any cause may produce delayed relaxation 
of deep tendon reflexes and similarly brain stem infarction in elderly may mimic 
myxedema coma. Mortality rate of myxedema coma is  20 % or more.11,12 Hence 
treatment should be initiated before getting results, on the clinical grounds. 
 
Bradycardia, 
decreased 
contractility & 
cardiac 
Output 
DECREASED BETA 
ADRENERGIC NUMBER &  
SENSITIVITY 
DECREASED PRODUCTION OF 
MYOCYTE CONTRACTILE 
PROTINS 
INCREASED ALPHA 
ADRENERGIC ACTIVITY 
LEADING TO 
VASOCONSTRICTION 
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TREATMENT: 
It involves hormone replacement and correction of physiological 
disturbances. Drug administrations should be through intravenous route, because 
of unpredictable absorption through oral, intramuscular route due to sluggish 
circulation. The patients are treated with levothyroxine as a single intra venous 
dose of 500 to 800 microgram. After this daily doses of 100 microgram of 
levothyroxine are given. Injection hydrocortisone 5 to 10 Mg per hour should also 
be given because of possibility of adrenocortical hormone deficiency. 
Avoid hypotonic fluids, because of water intoxication due to 
decreased water clearence.  Hypertonicfluids may be given to treat dilutional 
hyponatremia. Respiratory support may be needed in the form of assisted 
ventilation. Avoid external warming, because it may lead to vascular collapse due 
to peripheral vasodilatation.  Blankets can be used to prevent heat loss. Internal 
warming should be avoided.  
CHANGES IN THYROID HORMONE METABOLISM THAT 
ACCOMPANY CARDIAC DISEASE 
In addition to the changes in thyroid function, which can result from 
classical, thyroid disease, there are primary alteration in serum total and free T3 
and occasionally serum T4 that accompany a variety of acute and chronic illnesses 
like sepsis, starvation and cardiac disease.  In the absence of Thyroid gland 
abnormality, changes in serum T3 levels result from alterations in thyroid 
hormone metabolism.  These cases have been referred to as “nonthyroidal illness.”  
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The mechanism for this decrease in serum T3 is multifactorial and in part related 
to a decrease in 5’ mono-deiodination in the liver. 
A wide variety of acute and chronic cardiac diseases can alter 
thyroid hormone metabolism associated with marked declines in serum T3.  A 
population –based study of patients with cardiac disease has shown that a low 
serum T3 level is a strong predictor of all-cause and cardiovascular mortality.13 
Following uncomplicated acute myocardial infarction, serum T3 levels fall by 
about 20 percent and reach a nadir after approximately 96 hours.  Experimental 
infarction in animal models produces a similar decrease in serum T3, and 
replacement of T3 levels to normal has been reported to increase left ventricular 
contractile function. 
Both children and adults undergoing cardiac surgery with 
cardiopulmonary bypass demonstrate a predictable fall in serum T3 in the 
preoperative period.  Although treatment strategies using acute administration of 
intravenous T3 to adults after coronary artery bypass grafting have resulted in an 
improvement in cardiac output and a fall in systemic vascular resistance, there was 
no alteration in overall mortality.  When the prevalence of atrial fibrillation was 
studied in this group of patients, however, it was shown to be decreased by as 
much as 50 percent compared with that in age-matched control subjects.  Pediatric 
cardiac patients, especially those undergoing surgery in the neonatal period, 
demonstrate an even greater decline in serum T3 that can last for longer periods of 
time.  The low postoperative T3 level identifies patients at increased risk for 
 18
morbidity and mortality.  A prospective randomized study has shown, especially 
in neonates, that the degree of therapeutic intervention and the need for 
postoperative inotropic agents are decreased by the administration of T3 in doses 
sufficient to restore serum T3 levels to normal. 
In patients with chronic congestive heart failure, the fall in serum T3 
is proportional to the severity of heart failure as assessed by the New York Heart 
Association classification.  As many as 30 percent of patients with heart failure 
have  a low serum T3, which occurs in both patients treated with amiodarone and 
those who are not.  In view of the deleterious effects of hypothyroidism on the 
myocardium, T3 replacement may be of benefit.  Human studies using a novel 
form of T3 that is capable of restoring serum T3 levels to normal and avoiding the 
peaks and valleys of drug levels associated with existing drug preparations are 
required to answer this question. 
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LIPIDS 
Cholesterol is a steroid. It is a precursor to many physiologically 
important steroids, such as bile acids and steroid hormones. Cholesterol synthesis 
initially involves the conversion of acetate to mevalonic acid. The rate limiting 
step is catalysed by the enzyme B – hydroxy methyl glutaryl co-enzyme a 
reductase (HM GCOA reductase), the activity of which is controlled by negative 
feedback by the intracellular cholesterol. About 2/3rds of the plasma cholesterol is 
esterified with fatty acids to form cholesterol esters. Assays in routine use 
measures the plasma total cholesterol concentrations and do not distinguish 
between the unesterified and esterified forms. Unlike that of triglyceride, plasma 
concentration of cholesterol do not rise after a fatty meal. 
Lipids are relatively insoluble in water; they are carried in body 
fluids as soluble protein complexes known as lipoproteins. The core of insoluble 
(nonpolar) cholesterol esters and triglycerides is surrounded by proteins, 
phospholipids and free cholesterol with their water-soluble (polar) groups facing 
outwards. 
CLASSIFICATION OF LIPOPROTEINS 
Classified according to their density. The greater the lipid/protein 
ratio in the complex, the larger it is and the lower its density. 
THERE ARE 5 MAIN CLASSES OF LIPOPROTEINS 
TRIGLYCERIDE – RICH PARTICLES 
1. CHYLOMICRONS – transport exogenous lipid from intestine to all cells. 
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2. VLDL (Very Low Density Lipoproteins), which transport endogenous lipid 
from the liver to cells. 
3. IDL (Intermediate density lipoproteins) usually undetectable in normal 
plasma. It is normally a transient intermediate lipoprotein formed during 
the conversion of VLDL to LDL. It contains both cholesterol and 
endogenous triglycerides. 
 
CHOLESTEROL – RICH PARTICLES 
4. LDL ( Low Density Lipoproteins) formed from VLDL; they transport 
cholesterol to cells. 
5. HDL ( High Density Lipoproteins) involved in transport of cholesterol 
from the cells to the liver. 
 
EXOGENOUS LIPID PATHWAYS 
Fatty acids and cholesterol, released by digestion of dietary fat 
together with cholesterol from bile are absorbed into intestinal mucosal cells 
where they are re-esterified to form triglycerides and cholesterol esters. These 
together with phospholipids, apo A, apo B are selected from cells into lymphatic 
system as chylomicrons. This secretion depends on the presence of apo B derived 
from HDL which are added to them in both lymph and plasma. 
 
 21
LDL is a small cholesterol – rich lipoprotein containing only apoB. 
It accounts for about 70% of total cholesterol in plasma. It is taken up by specific 
receptors on cell surfaces (LDL receptors or apo B/E receptors). These receptors 
are present in all cells, especially abundant in liver. They recognize apo B and apo 
E and so can take up LDL or IDL. After entering the cells LDL is broken down by 
lysosomes and the released cholesterol is used up for membrane formation and 
synthesis of steroid hormones. Cholesterol taken up by receptors, inhibits 
intracellular cholesterol synthesis and prevents further uptake by reducing the rate 
of synthesis of LDL receptors. Most of the plasma LDL is removed by LDL 
receptors. But if plasma concentrations are high some may also enter cells by a 
passive unregulated route. Due to their small size they can infiltrate tissues such as 
arterial wall and cause damage. 
 
FACTORS INFLUENCING PLASMA LDL CONCENTRATION  
Plasma LDL & therefore plasma cholesterol concentration is 
determined mainly by rate of uptake of LDL by LDL receptors. 
LIVER  has central role in cholesterol metabolism because it  
• Contains most of the LDL receptors 
• Synthesizes most of the endogenous cholesterol  
• Receives cholesterol from diet and from lipoproteins 
• Is the only organ that can excrete cholesterol from the body in bile. 
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The concentration of LDL receptors on the hepatic cell surface 
depends on the amount of cholesterol in the cells. As intracellular cholesterol 
accumulates, the number of receptors is reduced. Factors that lead to cholesterol 
accumulation in the liver will, by reducing the receptor numbers, increase plasma 
LDL concentrations. One of these factors is the amount of cholesterol reaching the 
liver from the intestine. 
  Between 30 and 60 percent of cholesterol entering the intestinal 
lumen from the diet and in the bile is absorbed. The rate of absorption increases if 
the diet is rich in saturated fat. 
Cholesterol may be secreted into plasma, incorporated into VLDL or 
excreted in bile as cholesterol or bile acids. Some bile acids are reabsorbed from 
the intestinal lumen and returned to liver via the enterohepatic circulation. 
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DYSLIPIDEMIA IN HYPOTYROIDISM 
Subclinical hypothyroidism results in small increase in LDL 
cholesterol and a decrease in HDL cholesterol which enhance the risk for 
developement of   atherosclerosis and coronary artery disease. These changes are 
due to action of thyroid hormone on lipid metabolism. In overt hypothyroidism, 
increase in total cholesterol, LDL, apolipoprotein B, Lipoprotein A and decrease 
in HDL occurs, where as in subclinical hypothyroidism increase in total 
cholesterol and LDL occurs, but no change in HDL or lipoprotein A.14 
 
ECG IN HYPOTHYROIDISM 
  Hypothyroidism tend to produce many ECG changes .The more 
common manifestations are  
  1 Sinus bradycardia. 
  2 . QT prolongation. 
  3 . Flat or Inverted T waves. 
The less common manifestations are : 
  1 . Heart Block. 
  2 . Low voltage QRS complexes. 
  3 . Intraventricular conduction defects. 
  4 . Ventricular premature depolarizations. 
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  There is decrease in the duration of depolarization in hypothyroidism 
which results in QT prolongation. Torsades de pointes reported in hypothyroidism 
is due to QT prolongation, hypothermia, electrolyte disturbances and 
hypoventilation. Non specific T wave changes are very common, which may be 
flat or inverted. But ST changes are not usually associated with T wave changes in 
hypothyroidism, unlike other causes. Duration of repolarization phase of action 
potential is greatly prolonged in atria of hypothyroidism which accounts for rarity 
of arrhythmias.15 Hypothyroidism has a significant antifibrillatory effect on 
ventricles in dogs.16 
OBESITY IN HYPOTHYROIDISM 
Increased weight gain is a well known feature of hypothyroidism. 
Because it is a risk factor for coronary artery disease, it is viewed with concern. 
Morbidly obese patients may present with abnormal thyroid function tests but the 
reported data are scarce. Marina A et al studied prevalence of hypothyroidism in 
morbidly obese individuals as 19.5 %. 
The reason why obesity occurs in hypothyroidism is due to 
myxedema. Myxedema is due to accumulation of hyaluronic acid which alters the 
composition of ground substance in tissues. This is hygroscopic that produces 
mucinous edema and thickening of skin.  
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PERICARDIAL EFFUSION 
  Pericardial effusion may be present in 30% of the patients in 
hypothyroidism. Pericardial effusion occurs due to increased capillary 
permeability. Usually pericardial effusion does not compromise cardiac output, 
and cardiac tamponade is very rare. Usually the pericardial effusion resolves after 
thyroid hormone replacement. 
 
CORONARY ARTERY DISEASE IN HYPOTHYROIDISM 
Because there are many risk factors like hypertension, obesity , 
hypercholesterolemia and hyperhomocystinemia,  hypothyroid patients are prone 
to coronary artery disease. There is a risk of atherosclerosis and myocardial 
infarction even in subclinical hypothyroidism.7 
ECHOCARDIOGRAPHY 
Echocardiography is one of the frequently used techniques for 
diagnosing cardiovascular diseases.  It is so versatile, with clinical application in 
the entire spectrum of cardiovascular diseases.  Echocardiography uses high 
frequency ultrasound to evaluate the structural, functional and homodynamic 
states of cardiovascular diseases. 
An echocardiographic examination begins with trans thoracic two 
dimensional (2D) scanning from four standard transducer positions:  the 
parasternal, apical, subxiphoid and suprasternal windows.  Quantitative 
measurements of cardiac dimensions, area and volume are derived from 2D 
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images or 2D derived M-mode.  In addition, 2D Echocardiography provides the 
framework for Doppler and color-flow imaging. 
Doppler Echocardiography measures blood-flow velocities in the 
heart and great vessels and is based on the Doppler Effect.  The most common 
uses of Doppler Echocardiography are pulsed and continuous waveforms.  Pulsed 
wave Doppler is used in determining peak-flow velocity, Valvular pressure 
gradient, pressure half-time, dynamic left ventricular outflow tract gradient, etc.  
Colour flow imaging based on Pulsed wave Doppler principles, displays 
intracavity blood flow in three colors (red, blue, green) or their combinations, 
depending on the velocity, direction and extent of turbulence.  Tissue Doppler 
provides means for measuring and displaying cardiac wall motion velocities.  
Tissue Doppler is used to evaluate regional and global diastolic function and it has 
been noted that mitral annulus velocity measured by Tissue Doppler is an indicator 
of myocardial relaxation, relatively unaffected by preload or after load. 
TREATMENT 
The response to treatment of hypothyroidism is predictable, 
especially from a cardiovascular perspective, Stepwise thyroid hormone 
replacement using levothyroxine sodium (Levoxyl, Synthroid) produces an 
incremental decrease in serum TSH, serum cholesterol, and serum CK and an 
improvement in left ventricular performance.  Full replacement is accomplished 
when serum TSH is normal.  In the rare condition of myxedema coma, which is 
characterized by severe and longstanding hypothyroidism with the development of 
 27
hypothermia, altered mental status, hypotension, bradycardia, and hypoventilation, 
the need for thyroid hormone replacement is more emergent and treatment can be 
accomplished with either T4 at 100ug/d or T3 25ug/d administered intravenously.  
These patients often require intensive care unit monitoring with volume repletion, 
gentle warming, and ventilatory support in the presence of CO2 retention.  
Administration of hydrocortisone (100 mg every 8 hours) should be undertaken 
until results of serum cortisol testing are obtained.  When patients are treated in 
this manner, hemodynamics including systemic vascular resistance, cardiac 
output, and heart rate improve within 24 to 48 hours. 
In contrast to overt symptomatic thyroid disease, subclinical thyroid 
disease implies the absence of classical hyper or hypothyrodism-related symptoms 
in patients with thyroid dysfunction.  The definition has been further refined to 
include the demonstration of an abnormal TSH level in the presence of normal 
serum levels of total T4 and free T4.  With the advent of widespread  TSH 
screening the magnitude of subclinical thyroid disease may exceed that of overt 
disease by three to fourfold. 
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MATERIALS AND METHODS 
 
 
 
  This study was conducted in patients with hypothyroidism who 
attended the endocrinology department in Stanley Medical College Hospital, 
Chennai, during the period November 2005 to July 2006.  
 
1. Patients who were newly diagnosed to have overt hypothyroidism were taken 
up for the study. 
 
2. Patients thus selected were divided into three categories according to the level 
of thyroid stimulating hormone (TSH) as follows:  
 
(i) Mild  hypothyroidism (< 20 mIU/ml) 
(ii) Moderate hypothyroidism (20 – 50 mIU/ml) 
(iii) Severe hypothyroidism (> 50 mIU/ml) 
 
                 
3. EXCLUSION CRITERIA - The following patients were     
 excluded from the study: 
•  Patients with known primary cardiac disease. 
•  Patients with chronic pulmonary disease, severe anemia, 
diabetes mellitus and chronic kidney disease. 
•  Patients who were taking drugs that alter the cardiovascular 
functions like amiadarone, Beta blockers and calcium channels 
blockers etc. 
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• Patients of hypothyroidism who were receiving thyroid 
replacement therapy. 
• Patients with subclinical hypothyroidism ( Normal T4 with 
elevated TSH). 
 
4. All the patients were evaluated for following parameters: 
• Pulse rate  
• Blood pressure - measured thrice and the average was taken (As per 
recommendations of Joint National Committee – 7) 
• Body mass index (< 25 is normal) 
• Serum free T4  (Normal Range – 4.5 to 12 ng/dl )  
• Serum TSH. (Normal Range – 0.3 to 5.2 mIU / ml) 
• Chest x ray 
• ECG  
• Total cholesterol  (As per recommendations  of American National 
Cholesterol Eradication Programe III)  
 
5. Echocardiography  was done in all the patients and the following parameters 
were looked for: 
a) Chamber size and wall thickness :  In the 2D and M-mode 
echocardiography, the measurements of the interventricular septum, left 
ventricular posterior wall thickness, left ventricular internal diameter 
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was made in both systole and diastole. Patients with interventricular 
septal thickness and left posterior wall thickness in diastole more than 
1.1 cm represent concentric hypertrophy. Asymmetric hypertrophy is 
defined as a ratio of interventricular septal thickness and left ventricular 
posterior wall thickness greater than 1.3. The parasternal long axis view, 
left ventricular internal diameter in diastole more than 5.6 cm represents 
dilated left venricle. Left atrial antero posterior diameter more than 
3.8cm represents dilated left atrium. 
b) Systolic function: The systolic function is assessed mainly by M-mode 
measurements. Ejection fraction and fractional shortening are the two 
parameters used. The ejection fraction is defined as the ratio of stroke 
volume to end diastolic volume. 
  
Ejection fraction = End diastolic volume - End systolic volume   
                               -----------------------------------------------------x100 
          End diastolic volume 
 
 Normal value of ejection fraction is between 55 to 75%.17 
        
  Grading of systolic dysfunction: 
 
               i) Mild    - EF   45 to   55 % 
               ii) Moderate  - EF    35 to   45% 
              iii) Severe      -  EF   < 35% 
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     Fractional shortening is calculated by the following equation: 
 
     Fractional shortening =  LVID(D) – LVID(S)  
               -------------------------   X 100 
                                                     LVID(D) 
 
 
c. Diastolic function: The diastolic function is assessed by Pulsed wave 
Doppler using the E/A Measurements. E (m/s)indicate mitral flow 
which causes ventricular filling      following opening of the mitral 
valve. A (m/s) indicates ventricular filling due to atrial systole. E/A is 
normally more than 1. Less than 1 indicates diastolic dysfunction. 
    Diastolic dysfunction can be graded as follows: 
 
        Grade 1 =  Impaired relaxation  
 
        Grade 2 =  Pseudonormalised  pattern 
 
        Grade 3 =  Reversible restrictive pattern. 
 
        Grade 4 =  Irreversible restrictive pattern 
 
d.  Left ventricular wall motion abnormalities: Left ventricular performance 
is assessed by many ways. Left ventricular wall is divided into a number 
of segments. Determining the motion of each segment provides the wall 
motion score. 
e.  Pericardial effusion:The pericardial effusion is quantified by the amount 
of echo free space surrounding the heart. The pericardial effusion can be 
graded as : 
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 Minimal pericardial effusion: Posterior atrio-ventricular groove 
shows echo free space, this is seen in systolic phase only.  It 
represents normal pericardial fluid.  
Mild pericardial effusion:    Echo free space < 1cm. 
 
Moderate pericardial effusion:  Echo free space 1 – 2 cm. 
. 
Large pericardial effusion:   Echo free space > 2cm 
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RESULTS : Total  of 40 patients were analyzed and the results were : 
 
TOTAL NUMBER OF PATIENTS - 40 
 
NUMBER OF MALES   - 10 (25%) 
 
NUMBER OF FEMALES  -  30 (75%) 
 
     
     TABLE  - 1 
  
         AGE AND SEX DISTRIBUTION 
 
 
AGE RANGE 
In YRS 
 
 
 
MALE 
 
 
FEMALE 
 
 
TOTAL 
(n-40) 
 
13 – 20 
 
0 
 
04 
 
04 (10%) 
 
21 - 30 
 
02 
 
12 
 
14 (35%) 
 
31- 40 
 
06 
 
09 
 
15(37.5%) 
 
41 - 50 
 
02 
 
05 
 
07 (17.5%) 
 
TOTAL 
 
 
10( 25%) 
 
30(75%) 
 
 
 
 
 
MEAN AGE - 32.5 Yrs       (RANGE - 13 TO 50 Yrs) 
 
About 72.5% of patients were in the age group of 21 to 40 years of age. 25% were 
males and 75% were females. 
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  BAR CHART SHOWING AGE DISTRIBUTION 
 
 
10%
35%
37.5%
17.5%
0
10
20
30
40
13-20 yrs 21-30yrs 31-40yrs 41-50yrs
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TABLE – 2 
 
 
SEVERITY OF HYPOTHYROIDISM 
 
 
 
GRADING 
(TSH in mIU/ml) 
 
 
TOTAL 
n – 40 ( %) 
 
MILD 
( < 20 ) 
 
 
06 
(15%) 
 
MODERATE 
( 20 – 50 ) 
 
 
17 
(42.5%) 
 
SEVERE 
( > 50 ) 
 
 
17 
(42.5%) 
 
 
MEAN - 48.78 mIU/ml  ( RANGE -9.3 – 135 mIU/ml) 
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PIE CHART SHOWING GRADING OF HYPOTHYROIDISM 
 
 
SEVERE 
42.5%
MODERATE 
42.5%
MILD 
15%
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TABLE-3 
HYPERTENSION IN HYPOTHYROID PATIENTS 
 
STAGES OF  
HYPERTENSION 
( BP in mm Hg) 
 
 
MALE 
 
 
FEMALE 
 
 
TOTAL 
(n-40) 
 
Pre Hypertension 
( 120 – 139/80-89) 
 
07 
 
09 
 
16 
(40%) 
 
Stage – I HTN 
(  140-159/90-99) 
 
03 
 
10 
 
13 
(32.5%) 
 
Stage - II HTN 
( > = 160/100 ) 
 
0 
 
02 
 
02 
(5%) 
 
TOTAL 
 n – 31 (%) 
 
10 
(32%) 
 
21 
(68%) 
 
 
 
MEAN – 125/82 mmHg ( RANGE : 80 – 170/ 60 – 110 mm Hg ) 
 
37.5 % of hypothyroid patients were hypertensive (BP >= 140/90 mm Hg) 
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TABLE  - 4 
 
BLOOD PRESSURE  AND SEVERITY OF HYPOTHYRODISM 
 
 
 
HYPOTHYROIDISM 
 
 
 
 
 
 
HYPERTENSION 
 
MILD 
n - 6 
 
 
MODERATE 
n - 17 
 
 
SEVERE 
n - 17 
 
 
PRE HTN 
 
 
02 
 
10 
 
04 
 
STAGE – I 
 
 
01 
 
01 
 
11 
 
STAGE – II 
 
 
0 
 
02 
 
0 
 
TOTAL 
 
 
03 (50%) 
 
13 (76%) 
 
15 (88%) 
 
 
 
Hypertension mostly occurred in severe hypothyroidism. 
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TABLE  - 5 
 
ECG CHANGES 
    
 
 
 
ABNORMALITIES 
 
 
TOTAL 
n – 40 (%) 
 
Sinus Bradycardia 
 
 
05 
(12.5%) 
 
1st degree AV block 
 
 
02 
(5%) 
 
ST Depression 
 
 
03 
(7.5%) 
 
RBBB 
 
 
01 
(2.5%) 
 
 
 
 
Sinus bradycardia was the most common ECG abnormality noted. 
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TABLE  - 6 
 
TOTAL CHOLESTEROL 
 
 
 
Total  
Cholesterol 
(mg/dl) 
 
 
MALE 
 
 
FEMALE 
 
 
TOTAL 
(n-40) 
 
< 200 
 
 
06 
 
16 
 
22 
(55%) 
 
200 – 239 
 
 
02 
 
09 
 
11 
(27.5%) 
 
>= 240 
 
 
02 
 
05 
 
07 
(17.5%) 
 
 
 
MEAN CHOLESTEROL – 204.5 mg/dl   (Range 143 – 290) 
 
 
 
45% of patients had hypercholesterolemia ( > = 200 mg/ dl) 
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TABLE – 7 
 
HYPERCHOLESTEROLEMIA IN HYPOTHYROIDISM 
   
 
HYPOTHYROIDISM 
 
Total 
Cholesterol 
(mg/dl) 
 
MILD 
n - 6 
 
 
MODERATE 
n - 17 
 
 
SEVERE 
n - 17 
 
 
200 – 239 
 
 
01 
 
04 
 
06 
 
>= 240 
 
 
0 
 
0 
 
07 
TOTAL 
( n- 18) 
O1 
(5.5%) 
04 
(22.2%) 
13 
(72.2%) 
 
 
 
72.2% of  hypercholesterolemia occurred in severe form of hypothyroidism 
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TABLE  - 8 
 
 
BODY MASS INDEX 
 
 
 
 
HYPOTHYROIDISM 
 
 
 
 
 
 
BODY MASS 
INDEX  
MILD 
n - 6 
 
 
MODERATE 
n - 17 
 
 
SEVERE 
n - 17 
 
 
 
 
 
TOTAL 
n-40 (%)  
 
< 25 
 
 
05 
 
08 
 
06 
 
19 
(47%) 
 
25 – 30 
 
 
0 
 
09 
 
07 
 
16 
(40%) 
 
> 30 
 
 
01 
 
0 
 
04 
 
05 
(12.5%) 
 
              
     
 
Gross obesity occurred only in 12.5% of hypothyroid patients. 
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TABLE  - 9 
 
 
SEPTAL WALL THICKNESS 
 
      
 
 
 
HYPOTHYROIDISM 
 
 
 
 
 
 
SEPTAL 
THICKNESS  
MILD 
n - 6 
 
 
MODERATE 
n - 17 
 
 
SEVERE 
n - 17 
 
 
 
 
 
TOTAL 
n-40 (%)  
 
< 9 mm 
 
 
0 
 
03 
 
0 
 
03 
(7.5%) 
 
9 – 11 mm 
 
 
05 
 
07 
 
05 
 
17 
(42.5%) 
 
> 11mm 
 
 
01 
 
07 
 
12 
 
20 
(50%) 
 
              
MEAN – 11mm ( RANGE – 7 – 14 mm) 
 
 
 
 
Septal hypertrophy occurred in 50% of the patients. 
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TABLE – 10 
 
 
LEFT VENTRICULAR  POSTERIOR  WALL THICKNESS 
 
 
 
 
HYPOTHYROIDISM 
 
 
 
 
 
 
POSTERIOR 
WALL 
THICKNESS 
 
MILD 
n - 6 
 
 
MODERATE 
n - 17 
 
 
SEVERE 
n - 17 
 
 
 
 
 
TOTAL 
n-40 (%)  
 
< 9 mm 
 
 
02 
 
06 
 
0 
 
08 
(20%) 
 
9 – 11 mm 
 
 
04 
 
08 
 
06 
 
18 
(45%) 
 
> 11mm 
 
 
0 
 
03 
 
11 
 
14 
(35%) 
 
              
MEAN – 10mm ( RANGE – 6 – 13 mm) 
 
 
 
 
 
Left ventricular posterior wall hypertrophy occurred in 35% of patients 
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TABLE – 11 
 
 
LEFT VENTRICULAR EJECTION FRACTION IN HYPOTHYROIDISM 
 
 
 
 
HYPOTHYROIDISM 
 
 
 
 
 
EJECTION 
FRACTION 
( % ) 
 
 
MILD 
n - 6 
 
 
MODERATE 
n - 17 
 
 
SEVERE 
n - 17 
 
 
 
 
 
TOTAL 
n-40 (%)  
 
< 55% 
 
 
0 
 
0 
 
01 
 
01 
(2.5%) 
 
55 – 60 % 
 
 
0 
 
03 
 
09 
 
12 
(30%) 
 
> 60 % 
 
 
06 
 
14 
 
07 
 
27 
(67.5%) 
 
              
MEAN – 63.3% ( RANGE – 52 – 73%) 
 
 
 
 
Most of the hypothyroid patients had normal left ventricular ejection fraction.  
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TABLE – 12 
 
 
FRACTIONAL SHORTENING IN HYPOTHYROIDISM 
 
 
 
 
HYPOTHYROIDISM 
 
 
 
 
 
FRACTIONAL 
SHORTENING 
( % ) 
 
 
MILD 
n - 6 
 
 
MODERATE 
n - 17 
 
 
SEVERE 
n - 17 
 
 
 
 
 
TOTAL 
n-40 (%)  
 
< 28% 
 
 
0 
 
0 
 
0 
 
0 
 
 
28 – 35 % 
 
 
0 
 
12 
 
14 
 
26 
(65%) 
 
> 35 % 
 
 
06 
 
05 
 
03 
 
14 
(35%) 
 
              
MEAN –  33.5% ( RANGE – 28  – 41%) 
 
 
 
 
Fractional shortening  is normal in all the patients 
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     TABLE – 13 
 
 
DIASTOLIC DYSFUNCTION IN HYPOTHYROIDISM 
 
 
 
 
HYPOTHYROIDISM 
 
 
 
 
 
E / A 
RATIO 
  
MILD 
n - 6 
 
 
MODERATE 
n - 17 
 
 
SEVERE 
n - 17 
 
 
 
 
 
TOTAL 
n-40 (%)  
 
< 1 
 
 
01 
 
03 
 
09 
 
13 
(32.5%) 
 
 
1– 1.5 
 
 
02 
 
09 
 
07 
 
18 
(45%) 
 
 
> 1.5  
 
 
03 
 
05 
 
01 
 
09 
(22.5%) 
 
 
              
MEAN – 1.2 (RANGE – 0.7 to 2.7) 
 
 
 
 
32.5% of patients had significant diastolic dysfunction 
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     TABLE – 14 
 
 
LEFT VENTRICULAR INTERNAL DIMENSION IN HYPOTHYROIDISM 
 
 
 
 
HYPOTHYROIDISM 
 
 
 
 
 
LV ID 
(D) 
IN cm  
MILD 
n - 6 
 
 
MODERATE 
n - 17 
 
 
SEVERE 
n - 17 
 
 
 
 
 
TOTAL 
n-40 (%)  
 
< 4cm 
 
 
01 
 
0 
 
02 
 
03 
(7.5%) 
 
 
4– 5cm 
 
 
05 
 
15 
 
08 
 
28 
(70%) 
 
 
> 5 cm 
 
 
0 
 
02 
 
07 
 
09 
(22.5%) 
 
 
              
MEAN – 4.6cm (RANGE – 3.4 – 5.2 cm) 
 
 
 
 
None of the patients had dilated left ventricle. 
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TABLE – 15 
 
SEPTAL WALL THICKNESS AND BLOOD PRESSURE 
 
 
AND BLOOD PRESSURE 
 
 
 
 
IVST 
 
PRE HTN 
 
STAGE - I STAGE - II 
 
>11mm 
 
 
06 
 
12 
 
02 
 
PERCENTAGE 
n - 20 
 
30% 
 
60% 
 
10% 
 
70% of patients with septal wall thickness had hypertension ( BP > = 140/90) 
     
TABLE – 16 
HYPERTENSION & DIASTOLIC DYSFUNCTION 
 
 
DIASTOLIC 
DYSFUNCTION 
 
PRE HTN 
 
STAGE – I 
HTN 
STAGE – II 
HTN 
 
NORMAL 
BP 
 
E/A < 1 
( n – 13 ) 
 
 02 
(15.4%) 
 
09 
( 69%) 
 
01 
(7.6%) 
 
01 
(7.6%) 
 
 
77 % of hypothyroid patients with diastolic dysfunction had hypertension.  
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TABLE – 17 
AGE AND WALL THICKNESS 
 
 
AGE IN YEARS 
 
 
MEAN IVST (D) 
cm 
 
MEAN LVPW (D) 
cm 
 
 
13 – 20 
 
0.82 
 
0.77 
 
 
21 - 30 
 
1.14 
 
1.02 
 
 
31- 40 
 
1.07 
 
1.01 
 
 
41 - 50 
 
1.26 
 
1.15 
 
The mean wall thickness increases with increasing age. 
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DISCUSSION 
Thyroid hormone exerts various actions on cardiovascular system. In 
hypothyroid state, the decreased myocardial contractility and increased peripheral 
vascular resistance along with bradycardia produces many changes in the heart. 
This study is undertaken to assess the cardiovascular changes in overt newly 
diagnosed primary hypothyroid patients attending endocrine department at Stanley 
Medical college hospital. 
A total of 40 newly diagnosed hypothyroid Patients were analyzed. 
There were 30 (75%) females and 10 (25%) males. The mean age of presentation 
was 32.5Years.The age range noted was between 13 to 50 years.73% of patients 
were in the age group of 21 to 40 Years of age.  The mean age for males was 35 
Years and for females 31 Years.  Most of the females 21 (70%) belonged to 21 to 
40 Years. Most common age group studied was 31 to 40 Years (37.5%).  
Of the 40 patients studied, 6 (15%) patients had TSH values of less 
than 20, classified as mild hypothyroidism. Moderate hypothyroidism (TSH 20-
50) and Severe Hypothyroidism (TSH more than 50) were present in 17 (42.5%) 
patients each.  Mean TSH value was 48.8 IU/L and the range of TSH noted was 
between 9.3 and 135 IU/L. 
15 (37.5%) patients had hypertension of which 13(32.5%) had stage 
I and 2(5%) stage II hypertension. 9(22.5%) had normal blood pressure. 16 (40%) 
had pre hypertension of which,7 were males and 9 females.  Out of 15 patients of 
hypertension, 12 (80%) were females and 3 (20%) were males.  The mean systolic 
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Blood Pressure was 125mm Hg and mean diastolic Blood Pressure was 82 mm 
Hg. The range of Systolic Blood Pressure noted was between 80 to 170mm Hg 
and diastolic Blood Pressure ranged from 60 to 110mm Hg.  Biondi et al reported 
a mean systolic Blood Pressure of 120mm Hg and mean diastolic pressure of 
78mm Hg.9 DH Streeten et al study observed a prevalence of 3.6% of 
hypothyroidism in a population of obesity.18 
Among 31 cases of hypertension, 16 (51.6%) had prehypertension, 
13 (41.9%) patients had stage 1 hypertension and 2 (6.4%) patients had stage II 
hypertension.  The incidence of hypertension in mild, moderate and severe 
hypothyroidism was 1 (16.6%), 3 (17.6%) and 11 (64%) in respective categories.  
There was no stage II hypertension in mild and moderate hypothyroidism.  In our 
study it has been found that hypertension commonly occurs with increasing 
severity of hypothyroidism (TSH levels).  Bergus et al reported no correlation 
between hypertension and TSH levels.19,20 Danzi S et al reported a 20 % diastolic 
hypertension in hypothyroidism.5 
16 (40%) patients were overweight (BMI 25-30), 5(12.5%) were 
obese (BMI > 30) and 19 (47%) patients had normal body mass index. Out of 16 
overweight patients, 7 (43.7%) had severe hypothyroidism and 9 (56.2%) had 
moderate hypothyroidism.  Out of 5 obese patients, 4 (80%) had severe 
hypothyroidismand 1 (20%) had mild hypothyroidism.  The mean body mass 
index noted was 25.7.  The mean body mass index noted in mild,  moderate and 
severe hypothyroidism were 23.8, 24.8 and 27.2 respectively.  In our study it was 
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observed that mean BMI increases with increasing levels of TSH. Marina A et al 
observed an incidence of 11% of hypothyroidism in obese individuals.21 
Various ECG abnormalities have been noted in patients with 
hypothyroidism in our study.  Most common abnormality was sinus bradycardia, 
which was noted in 5(12%) patients. Other ECG  abnormalities noted were ST 
depression in 3 (7.5%) patients and  1st Degree heart block in 2 (5%).  Only one 
patient had Right Bundle Branch Block .No patient had low voltage QRS complex 
or QT prolongation. 
  Hypercholesterolemia ( > 200 mg/dl) was noted in 18 (45%) patients 
of which 11 (27.5%) had serum cholesterol between 200- 239 and 7 (17.5%) had 
Cholesterol level more than 240. 22 (55%) patients had normal cholesterol level.    
The mean cholesterol level noted was 204.5 mg / dl.  The range of cholesterol 
level was from 143 to 290 mg / dl. Out of 18 patients with hypercholesterolemia 
13 had severe hypothyroidism, 4 had moderate and 1 had mild hypothyroidism. 
76% of severely hypothyroid patients had serum cholesterol more than 200 mg/dl.     
The mean cholesterol level in mild, moderate and severe 
hypothyroidism were 174.3 mg /dl,191 mg / dl and 229 mg / dl respectively.   
Cholesterol level above 240 was present in only in severe hypothyroid patients. In 
our study the cholesterol level increases with increasing levels of TSH. Kung et al 
reported an incidence of 50% of   hyperlipoprotinemia in subclinical 
hypothyroidism.22 
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ECHOCARDIOGRAPHIC PROFILE 
INTERVENTRICULAR SEPTAL WALL THICKNESS: 
Most common abnormality noted in echocardiography is septal wall 
thickness.  50% of patients had increased septal wall hypertrophy. Septal wall 
thickness more than 11 mm  was noted in 20(50%) patients, between 9-11mm in 
17(42.5%) patients and less than 9mm in 3(7.5%) patients. The mean septal wall 
thickness was 11mm. The mean septal wall thickness in mild, moderate and severe 
hypothyroidism was 10 mm, 10 mm and 11 mm respectively.  The range of septal 
wall thickness was from 7 mm to 14 mm. Out of 20 patients who had septal wall 
hypertrophy 12 had severe hypothyroidism , 7 had moderate and one had mild 
hypothyroidism. 70% of severe hypothyroid and 42.5% of moderately hypothyroid 
patients had septal wall hypertrophy. In our study there is a steady increase in 
septal wall thickness with increasing severity of hypothyroidism. Varma et al had 
reported a mean septal wall thickness of 0.91 cm in moderate and 0.97 cm in 
severe hypothyroidism patients.23 
 Biondi et al reported a mean septal wall thickness of 0.98 cm in 
subclinical hypothyroid patients.9 Rawat et al reported a mean septal wall 
thickness 1.2 cm in hypothyroid patients.24   
LEFT VENTRICULAR POSTERIOR WALL THICKNESS: 
14 (35%) patients had Left ventricular posterior wall thickness of 
more than 11mm, 18(45%) patients had 9-11mm and 8(20%) patients had less 
than 9mm thickness. Out of 14 patients who showed Left ventricular posterior 
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wall hypertrophy, 11 (78.5%) had severe hypothyroidism, 3 (21.5%) had moderate 
hypothyroidism and none of the mild hypothyroid patient showed Left ventricular 
posterior wall hypertrophy. 65% of severely hypothyroid and 17% of moderately 
hypothyroid patients  had left ventricular posterior wall hypertrophy. 
Mean Left ventricular posterior wall thickness was 1.018 cm.  The 
mean Left ventricular posterior wall thickness in mild, moderate and severe 
hypothyroidism noted were 0.88 cm, 0.98 cm and 1.09 cm respectively.  The ratio 
of septal hypertrophy and Left ventricular posterior wall thickness more than 1.3 is 
termed as Asymmetric hypertrophy.  In our study the ratio of septal hypertrophy 
and Left ventricular posterior wall thickness was less than 1.3.  So there was 
symmetrical hypertrophy of septal and Left ventricular posterior wall.  Rawat et al, 
Biondi et al and Varma et al noted a mean Left ventricular posterior wall thickness 
of 1.1 cm., 0.89 cm and 1.3 cm respectively in their study of hypothyroid 
patients.24,9,23 
SYSTOLIC DYSFUNCTION: 
Most of the patients ( 97.5%) of patients had Ejection Fraction more 
than 55%, of which 12(30%) patients had ejection fraction between 55 – 60% and 
27 (67.5%) patients had ejection fraction of more than 60%. Only one patient 
(2.5%) had ejection fraction less than 55% ,who was severely hypothyroid.  The 
mean ejection fraction was 63.3%.  The mean ejection fraction in mild, moderate 
and severe hypothyroidism was 69%, 63.5% and 61%.  These observations led to a 
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conclusion that systolic function was less affected in hypothyroidism.  The mean 
ejection fraction of left ventricle noted in Rawat et al study was 59%.24 
Among 40 patients of hypothyroidism none of the patients had 
fractional shortening of less than 28%.  Fractional Shortening between 28 to 35% 
and more than 35% was noted in 26(65%) and 14(35%) patients respectively.  The 
mean Fractional Shortening was 33.5% ranging between 28 – 41 %.  The mean 
Fractional Shortening in mild, moderate and severe hypothyroidism noted were 
39.17%, 34.29% and 33.12% respectively.  Fractional Shortening is not 
significantly affected in hypothyroidism in the present study. Biondi et al and 
Rawat et al  noted a  mean Fractional Shortening of 37% and 27.3% respectively 
in their study of hypothyroid patients.9,24 Grossman et al (1994) and Varma et al 
(1995) did not find any evidence of systolic dysfunction in hypothyroid 
patients.25,23 
 
DIASTOLIC DYSFUNCTION: 
13 (32.5%) patients had a E/A ratio of less than 1, 18(45%) had 
between 1 to 1.5 and 9(22.5%) had more than 1.5.  Out of 13 patients who showed 
diastolic dysfunction ( E/A ratio < 1) 9 were severely hypothyroid and 3 were 
moderately hypothyroid. 53% of severely hypothyroid patients and 18% of 
moderately hypothyroid patients had diastolic dysfunction. The mean E/A ratio 
was 1.2.  The range of E/A ratio varied from 0.7 to 2.7. The mean E/A ratio 
observed in Bernadette Biondi et al study was 1.3 cm in sub clinical 
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hypothyroidism.9 Varma et al from safdarjang Hospital New Delhi observed 
diastolic dysfunction in significant number of patients in overt hypothyroidism.23  
Diastolic dysfunction is second most common abnormality after septal and 
posterior wall thickness in hypothyroidism.   
 
LEFT VENTRICULAR DILATATION: 
3 (7.5%) patients had left ventricle internal dimension in diastole of 
less than 4 cm, 28 (70%) had left ventricle internal dimension in diastole of 4 - 5 
cm, and 9 (22.5%) had left ventricle internal dimension in diastole of more than 5 
cm.  But none of the patients had more than 5.5 cm. of  left ventricle internal 
dimension in diastole, which indicates left ventricular enlargement.  The mean left 
ventricular internal dimension was 4.7 cm and the range was from 3.4 cm to 5.2 
cm.  Rawat et al noted the mean left ventricle internal dimension in diastole of 5.5 
cm.24  Biondi et al noted a mean left ventricle internal dimension in diastole of 4.7 
cm.9  To conclude left ventricle internal dimension in diastole has no changes in 
the present study as what was observed in varma R et al study.23 
 
PERICARDIAL EFFUSION: 
Pericardial effusion was found in 3 (7.5%) cases.  Of these 3 
patients, 2 of them were moderately hypothyroid and 1 had severe 
hypothyroidism.  All the 3 patients with Pericardial effusion had only mild 
Pericardial effusion, which is defined as an echo space of less than 1 cm. Hardisty 
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et al studied 39 patients and observed Pericardial effusion in 12 (30.7%) patients, 
who were severely hypothyroid.26  Kabadi et al noted Pericardial effusion only in 
3 and 6% in mild and severe hypothyroidism respectively.27  But Rawat et al 
observed Pericardial effusion in 72% of patients with hypothyroidism but no 
pericardial effusion in patients less than 30 years.24 Varma et al reported 
Pericardial effusion only in overt hypothyroidism.23 Fouron et al pointed out low 
incidence of pericardial effusion in young patients.28 
 
AGE AND WALL THICKNESS: 
Literature shows that there are increased incidence of asymmetric or 
concentric wall thickness in hypothyroid patients but latter it was pointed out that 
most of the patients were relatively older, and most of them might have age related 
wall thickening.  Studies done by Bennet et al, Lee et al, and Bernstein et al did 
not find significant wall thickness in young individuals.29,30,31 
In our study, the mean septal wall thickness noted in the age groups 
13-20 yrs, 21-30, 31- 40 and 41-50 were 0.82 cm, 1.14cm , 1.07cm and 1.26cm 
respectively.The mean left ventricular posterior wall thickness noted in the age 
groups 13-20 yrs, 21-30, 31- 40 and 41-50 were  0.77 cm,1.02cm, 1.01cm and 
1.1cm respectively.  These observations make it clear that there is increase in 
mean septal wall thickness with increasing age, as what was suggested by Rawat 
et al.24     
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Among these 20 patients with Septal hypertrophy, Pre Hypertension 
was present in 6 (30%) patients and the remaining 14 (70%) had Hypertension. 
Out of 13(32.5%) patients with diastolic dysfunction,10 (77%) had hypertension, 2 
(15.4%) had Pre Hypertension and 1 (7.6%) had normal Blood Pressure.   
This study highlighted the role of echocardiography in assessing the 
cardiovascular changes that occur in hypothyroidism. The most common 
abnormality observed was septal and LV posterior wall hypertrophy. Diastolic 
dysfunction was noted in significant number of patients. There was no systolic 
dysfunction or left ventricular dilatation.  
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SUMMARY 
 
 
1. A total of 40 patients were analyzed. There were 30 females and 10 males. 
Mean age of presentation was 32.5 years. 
2. There were 15 % Mild hypothyroidism,42.5% Moderate hypothyroidism and 
42.5 % Severe hypothyroidism patients.  
3. 40% of patients were overweight and 12.5 % of patients were obese. 
4. Hypercholesterolemia occurred in 45 % and Hypertension occurred in 37.5 %. 
5. Chest xray was normal in all patients. 
6. Commonest ECG abnormality noted was sinus bradycardia . 
7. In echocardiographic study,  interventricular septal wall and left ventricular 
posterior wall hypertrophy  noted in 50 % and 35 % of patients respectively. 
8. Diastolic dysfunction was observed in 32.5 % ( E/A ratio < 1) 
9. Grade 1 systolic dysfunction was noted only in one patient(2.5 %). 
10.  Pericardial effusion occurred in  3 patients (7.5 %). 
11.  Dilated left ventricle / left atrium or regional wall motion abnormalities were 
not found in any patient. 
 
 
 
 
 
 
 
 
 62
     CONCLUSION 
 
 
 
• Echocardiography is easily performed, noninvasive, safe, reproducible and 
accurate in assessment of cardiac function in hypothyroidism. 
 
• Hypertrophy of interventricular septum and left ventricular posterior wall 
was the commonest abnormality observed in echocardiography. 
 
• Diastolic dysfunction occurred in significant number of hypothyroid 
patients. 
 
• The cardiovascular changes were more marked in severe hypothyroidism. 
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PROFORMA 
 
Name :     Age:    Sex: 
TSH LEVEL  
T 4 LEVEL 
Clinical Features: 
• HEIGHT 
• WEIGHT 
• BMI 
• PULSE RATE 
• BLOOD PRESSURE 
Laboratory profile 
• ECG 
• CHEST X RAY 
• SERUM TOTAL CHOLESTEROL 
• ECHOCARDIOGRAPHY –  Septal wall thickness 
      Posterior wall thickness 
      Fractional shortening 
      Ejection fraction 
      Diastolic dysfunction (E/A ratio ) 
      LVID 
      Pericardial effusion 
      RWMA  
